Lung Cancer Found in Eye: Ex-Triathlete Beats Odds

A former Ironman triathlete, Dave Nitsche, 57, received a shocking stage 4 lung cancer diagnosis in 2019, with doctors initially providing a prognosis of 12 to 24 months. His first symptom was vision loss in his left eye, which specialists initially believed to be a detached retina. Scans revealed fluid buildup and pressure, leading to the removal of the eye and a subsequent biopsy that confirmed cancer.

Nitsche's diagnosis was particularly surprising as he is a non-smoker. Specialists confirmed the eye issue stemmed from lung cancer, a rare presentation. After initial treatments with afatinib and then Tegrisso (osimertinib) for brain metastasis, Nitsche has been undergoing treatment with the experimental drug Rybrevant (amivantamab) via IV infusion for the past year. This therapy has shown significant positive results, surpassing his initial prognosis by several years.

Rybrevant, approved for certain non-small cell lung cancers in the U.S. and Canada, has been effective for Nitsche, with manageable side effects like skin irritation and nail infections. He is now preparing for a 600-mile biking expedition to raise lung cancer awareness, crediting his fitness and endurance training for his extended survival. Nitsche advocates for self-advocacy in cancer treatment, emphasizing that a diagnosis is not always a death sentence due to ongoing research.